Journal
JOURNAL OF MEDICAL VIROLOGY
Volume 90, Issue 2, Pages 367-371Publisher
WILEY
DOI: 10.1002/jmv.24948
Keywords
antibodies; coronaviruses; immunity; MERS-CoV; serology; surveillance
Categories
Funding
- National Center for Immunization and Respiratory Diseases
Ask authors/readers for more resources
The Centers for Disease Control and Prevention (CDC) algorithm for detecting presence of serum antibodies against Middle East Respiratory Syndrome coronavirus (MERS-CoV) in subjects with potential infections with the virus has included screening by indirect ELISA against recombinant nucleocapsid (N) protein and confirmation by immunofluorescent staining of infected monolayers and/or microneutralization titration. Other international groups include indirect ELISA assays using the spike (S) protein, as part of their serological determinations. In the current study, we describe development and validation of an indirect MERS-CoV S ELISA to be used as part of our serological determination for evidence of previous exposure to the virus.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available